DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12

Size: px
Start display at page:

Download "DCP MIDSTREAM, LP FORM 8-K. (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12"

Transcription

1 DCP MIDSTREAM, LP FORM 8-K (Current report filing) Filed 04/13/12 for the Period Ending 04/09/12 Address TH STREET SUITE 2500 DENVER, CO, Telephone CIK Symbol DCP SIC Code Natural Gas Transmission Industry Oil & Gas Transportation Services Sector Energy Fiscal Year 12/31 Copyright 2018, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.

2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 9, 2012 DCP MIDSTREAM PARTNERS, LP (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.) th Street, Suite 2775 Denver, Colorado (Address of principal executive offices) (Zip Code) (303) (Registrant s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

3 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 12, 2012, DCP Midstream Partners, LP (the Partnership ) issued a press release, announcing that Angela A. Minas, Vice President and Chief Financial Officer of DCP Midstream GP, LLC ( DCP Midstream GP ), the Partnership s general partner, has decided to leave the Partnership effective May 11, 2012 to pursue other interests, and that Rose M. Robeson was appointed Senior Vice President and Chief Financial Officer of DCP Midstream GP, also effective May 11, Ms. Robeson, age 51, is currently the Group Vice President, Chief Financial Officer of DCP Midstream, LLC, the owner of DCP Midstream GP, and has served in that position since Prior to that time she was Vice President, Treasurer of DCP Midstream, LLC from 2000 to Prior to joining DCP Midstream, LLC, Ms. Robeson was with Kinder Morgan (formerly KN Energy) from 1996 to 2000, where she served as Vice President and Treasurer from 1998 to Prior that time she served in a number of finance positions at Total Petroleum from 1987 to She began her career as a certified public accountant with Ernst & Young. Ms. Robeson has nearly 30 years of experience in finance and 25 years of experience in the energy industry. Ms. Robeson will receive an annual base salary of $293,000 in her new position. In addition, she will participate in the Partnership s short term cash incentive program with a target incentive opportunity of 50% of her base salary, pro-rated for 2012 based on the percentage of the year she works for the Partnership. Ms. Robeson will participate in the DCP Midstream, LLC long term incentive plan for 2012 and is then expected to participate in the Partnership s long term incentive plan for The press release announcing Ms. Minas departure and the appointment of Ms. Robeson is attached hereto as Exhibit The information in Exhibit 99.1 is being furnished pursuant to this Item Item 9.01 Financial Statements and Exhibits. (d) Exhibit No. Exhibits. Description 99.1 Press Release dated April 12, 2012.

4 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 13, 2012 DCP MIDSTREAM PARTNERS, LP By: DCP MIDSTREAM GP, LP, its General Partner By: DCP MIDSTREAM GP, LLC, its General Partner By: /s/ Michael S. Richards Name: Michael S. Richards Title: Vice President, General Counsel, and Secretary

5 EXHIBIT INDEX Exhibit No. Description 99.1 Press Release dated April 12, 2012.

6 Exhibit 99.1 April 12, 2012 DCP Midstream Partners CONTACT: DCP Midstream CONTACT: News Release th Street, Suite 2500 Denver, CO Jonni Anwar Lisa Newkirk DCP MIDSTREAM PARTNERS, LP AND DCP MIDSTREAM, LLC ANNOUNCE MANAGEMENT CHANGES DENVER, April 12, 2012 DCP Midstream Partners, LP (NYSE: DPM) (the Partnership) and DCP Midstream, LLC (DCP Midstream), the owner of the general partner of the Partnership, announced today that effective May 11, 2012, Angela A. Minas, the Partnership s vice president and CFO, has decided to leave the Partnership to pursue other interests and Rose M. Robeson, currently group vice president and CFO of DCP Midstream, will be appointed to the position of senior vice president and CFO of the Partnership. In conjunction with this move and as part of periodic rotational management changes within the overall DCP enterprise, Sean O Brien, currently vice president financial planning and analysis and treasurer of DCP Midstream, will be appointed to the position of senior vice president and CFO of DCP Midstream. O Brien joined DCP Midstream in 2009 from Duke Energy, where O Brien served in several senior financial leadership positions. In addition, Scott Delmoro, who is currently in a developmental role in the commercial organization, will become vice president and treasurer of DCP Midstream. Delmoro also previously served as the vice president and controller of DCP Midstream. We would like to thank Angela for her significant contributions to the Partnership s successful execution of its growth strategy. During Angela s three years with the Partnership she performed a crucial role in the design and execution of our financing plan and positioning the Partnership for success. We are also very pleased to have Rose, who has overseen DCP Midstream s overall financial plans and relationships with its investors and commercial banks, rotate within the DCP enterprise to provide a seamless transition to the role of senior vice president and CFO of the Partnership. Rose brings a wealth of experience to the Partnership having over 25 years of industry experience, most recently as the group vice president and CFO of DCP Midstream for the past 10 years, said Mark Borer, president and CEO of the Partnership. Robeson also previously served in leadership positions at Total Petroleum and Kinder Morgan (formerly KN Energy). About DCP Midstream Partners, LP DCP Midstream Partners, LP (NYSE: DPM) is a midstream master limited partnership engaged in the business of gathering, compressing, treating, processing, transporting, storing and selling natural

7 gas; producing, fractionating, transporting, storing and selling NGLs and condensate; and transporting, storing and selling propane in wholesale markets. DCP Midstream Partners, LP is managed by its general partner, DCP Midstream GP, LLC, which is wholly owned by DCP Midstream, LLC, a joint venture between Spectra Energy and ConocoPhillips. For more information, visit the DCP Midstream Partners, LP website at About DCP Midstream, LLC DCP Midstream, LLC with headquarters in Denver, leads the midstream segment as the second-largest natural gas gatherer and processor, the largest natural gas liquids producer and one of the largest marketers in the United States. DCP Midstream operates in 18 states across major producing regions. DCP Midstream is a 50:50 joint venture between Spectra Energy and ConocoPhillips. The company owns the general partner of DCP Midstream Partners LP, a master limited partnership, and provides operational and administrative support to the partnership. DCP Midstream is the largest oil and gas company, the largest private company and one of the Best Places to Work in Denver as ranked by the Denver Business Journal. For more information, visit the DCP Midstream website at ### -2-

WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006

WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006 WALGREEN CO FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006 Address 200 WILMOT RD DEERFIELD, Illinois 60015 Telephone 847-940-2500 CIK 0000104207 Industry Retail (Drugs)

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): February1,2016

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Capital Senior Living Corporation

Capital Senior Living Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

WALGREENS BOOTS ALLIANCE, INC.

WALGREENS BOOTS ALLIANCE, INC. WALGREENS BOOTS ALLIANCE, INC. FORM 8-K (Current report filing) Filed 01/30/17 for the Period Ending 01/26/17 Address 108 WILMOT ROAD DEERFIELD, IL 60015 Telephone (847) 315-2500 CIK 0001618921 Symbol

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter)

VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

RULES OF CONDUCT OF INSIDERS RESPECTING

RULES OF CONDUCT OF INSIDERS RESPECTING T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington D.C FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2009 Commission

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT

More information

Oragenics, Inc. (Exact name of registrant as specified in its charter)

Oragenics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 25, 2018

More information

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT

More information

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event

More information

CONSTITUTION ARTICLE I NAME AND LOGO ARTICLE II OBJECTIVES AND PURPOSES ARTICLE III MEMBERSHIP

CONSTITUTION ARTICLE I NAME AND LOGO ARTICLE II OBJECTIVES AND PURPOSES ARTICLE III MEMBERSHIP ARTICLE I NAME AND LOGO CONSTITUTION The name of the Society is Cameroon Radiological Protection Society which is created in 28 th September 2012 may be referred to in abbreviated form as CRPS. The logo

More information

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515 February 28, 2018 The Honorable Michael Burgess, M.D. The Honorable Gene Green Chairman Ranking Member Subcommittee on Health Subcommittee on Health House Committee on Energy and Commerce House Committee

More information

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Neuralstem, Inc. (Exact name of registrant as specified in Charter)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. Neuralstem, Inc. (Exact name of registrant as specified in Charter) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

More information

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

VolitionRx Announces First Quarter 2016 Financial Results and Business Update May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused

More information

Chapter Affiliation Annual Report Workbook

Chapter Affiliation Annual Report Workbook 2017 Chapter Affiliation Annual Report Workbook International Association of Workforce Professionals 3267 Bee Caves Road Suite 107-104 Austin, Texas 78746 info@iawponline.org Phone 1-888-898-9960 Letter

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

TRAUMA RECOVERY/HAP OPERATING GUIDELINES TRAUMA RECOVERY/HAP OPERATING GUIDELINES FOR THE NATIONAL TRAUMA RECOVERY NETWORK, THE TRAUMA RECOVERY NETWORK ASSOCIATIONS, AND THE TRAUMA RECOVERY NETWORK CHAPTERS Operating Guidelines These Operating

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --

-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks -- Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial

More information

DISCOVER THE BENEFITS OF MEMBERSHIP

DISCOVER THE BENEFITS OF MEMBERSHIP Join us. DISCOVER THE BENEFITS OF MEMBERSHIP What's In it For You? Over 200 member organizations enjoy benefits through membership in the California Transit Association. We encourage you to join our expanding

More information

Do not edit or delete any questions from this application. Doing so will result in immediate disqualification of your request.

Do not edit or delete any questions from this application. Doing so will result in immediate disqualification of your request. AIDS Walk of Oklahoma City, Inc. Request for Proposal (RFP) 2018 Proposal Application (for funding year 2019) Deadline: October 31, 2018 NOT VALID AFTER OCTOBER 31, 2018 General instructions can be downloaded

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

CytoDyn Inc. (Exact name of registrant as specified in its charter)

CytoDyn Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event

More information

We are a network of successful REALTORS, advancing women as professionals and leaders in business, the industry and the communities we serve.

We are a network of successful REALTORS, advancing women as professionals and leaders in business, the industry and the communities we serve. We are a network of successful REALTORS, advancing women as professionals and leaders in business, the industry and the communities we serve. Dear Business Professional: It is a pleasure to invite you

More information

New Markets Tax Credit CDE Certification Question & Answer

New Markets Tax Credit CDE Certification Question & Answer Community Development Financial Institutions Fund New Markets Tax Credit CDE Certification Question & Answer Revised July 2005 Page 1 of 10 Table of Contents General Application and Eligibility Questions

More information

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-

More information

Corporate Membership Application

Corporate Membership Application Our Vision Corporate Membership Application The Rotary Club of Calgary (the Club ) is an organization of business, professional, and community leaders who come together through commitment and fellowship

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month

More information

Report to the GAVI Alliance Board 7-8 July 2011

Report to the GAVI Alliance Board 7-8 July 2011 Report to the GAVI Alliance Board 7-8 July 2011 Subject: Report of: Authored by: GAVI Matching Fund for Immunisation David Ferreira, MD, Innovative Finance Paolo Sison, Director, Innovative Finance Agenda

More information

STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS. Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails

STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS. Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails NOTICE OF GRANT OPPORTUNITY (Updated) Announcement Date: September

More information

GENERAL INFORMATION AND INSTRUCTIONS

GENERAL INFORMATION AND INSTRUCTIONS NON-PARTICIPATING MANUFACTURER CERTIFICATION FOR LISTING ON OREGON DIRECTORY GENERAL INFORMATION AND INSTRUCTIONS Who is required to file this Certification? Any tobacco product manufacturer who is a non-participating

More information

2006 Annual Report. Anastomosis Made Simple

2006 Annual Report. Anastomosis Made Simple 2006 Annual Report R Anastomosis Made Simple Cardica designs and manufactures proprietary automated anastomosis systems used by surgeons to perform rapid, reliable and consistent connections, or anastomoses,

More information

National Association of the Deaf NAD BOARD OF DIRECTORS MEETING Freemont, California October 12, 2012

National Association of the Deaf NAD BOARD OF DIRECTORS MEETING Freemont, California October 12, 2012 National Association of the Deaf NAD BOARD OF DIRECTORS MEETING Freemont, California October 12, 2012 President Wagner called the board meeting to order at 9: 05 AM PST. Board Members Present: Chris Wagner,

More information

2017 District 44 Mid-Year TLI

2017 District 44 Mid-Year TLI 2017 District 44 Mid-Year TLI Pre-Work Part I of II TLI Pre-Work Objectives Thank you registering for one of our upcoming District 44 Toastmasters Leadership Institute club officer trainings.! Pre-work

More information

FEDERAL NATIONAL MORTGAGE ASSOCIATION FANNIE MAE

FEDERAL NATIONAL MORTGAGE ASSOCIATION FANNIE MAE FEDERAL NATIONAL MORTGAGE ASSOCIATION FANNIE MAE FORM ABS-15G/A (Amended Disclosure of Asset-Backed Securities) Filed 05/09/18 Address 3900 WISCONSIN AVE N.W. WASHINGTON, DC, 20016 Telephone 2027527000

More information

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)

PIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

2017 District 44 Summer TLI

2017 District 44 Summer TLI 2017 District 44 Summer TLI Pre-Work Part I of II TLI Pre-Work Objectives Thank you registering for one of our upcoming District 44 Toastmasters Leadership Institute (TLI) club officer trainings. Pre-work

More information

A NIGHT WITH THE STARS SPONSORSHIP PACKET

A NIGHT WITH THE STARS SPONSORSHIP PACKET A NIGHT WITH THE STARS SPONSORSHIP PACKET Help us break the cycle of homelessness in San Francisco APRIL 9 TH, 2014 MINER AUDITORIUM SFJAZZ CENTER SAN FRANCISCO, CA A New Venue, A New Theme & Six New Talented

More information

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

MDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46

MDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46 The Michigan Department of Community Health Institutional Review Board for the Protection of Human Research Subjects Capitol View Building, 7 th Floor, 201 Townsend Street, Lansing, MI 48913 Phone: 517/241-1928

More information

Standards of Conduct for Transmission Providers

Standards of Conduct for Transmission Providers Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission

More information

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

Broad and clinically important benefits beyond the initial registrational endpoints are now reported. Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom

More information

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15. [NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS

More information

Business Partner Program WELCOME Thank you for your interest and support of the Denver legal community!

Business Partner Program WELCOME Thank you for your interest and support of the Denver legal community! 2018-2019 Business Partner Program WELCOME Thank you for your interest and support of the Denver legal community! OVERVIEW OF Mile High Chapter Business Partners receive benefits based on their level of

More information

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with

More information

RESOLUTION NO A RESOLUTION APPROVING REFERAL TO THE ELECTORS OF THE CITY OF ALBANY THE

RESOLUTION NO A RESOLUTION APPROVING REFERAL TO THE ELECTORS OF THE CITY OF ALBANY THE RESOLUTION NO. 6527 A RESOLUTION APPROVING REFERAL TO THE ELECTORS OF THE CITY OF ALBANY THE QUESTION OF IMPOSING A TAX ON THE SALE OF MARIJUANA ITEMS BY A MARIJUANA RETAILER WITHIN THE CITY RECITALS:

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

DELTA DENTAL PREMIER

DELTA DENTAL PREMIER DELTA DENTAL PREMIER PARTICIPATING DENTIST AGREEMENT THIS AGREEMENT made and entered into this day of, 20 by and between Colorado Dental Service, Inc. d/b/a Delta Dental of Colorado, as first party, hereinafter

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

Avenue Therapeutics, Inc. August 2016

Avenue Therapeutics, Inc. August 2016 Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe

More information

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 Price- $6,330,275 Cap Rate-5.45% Absolute Net Lease with 19 Years Remaining on Initial Lease Term. Lease Guaranteed by Walgreen

More information

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

More information

YOUR RESPONSIBILITIES

YOUR RESPONSIBILITIES CLUB PRESIDENT You will want to assume the most important office in your Optimist Club with enthusiasm and the desire to make your administrative year the best in Club history. You can, if you begin planning

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains

More information

OVERSEAS SCHOOL OF COLOMBO SCHOOL COMMUNITY NETWORK (SCN) CONSTITUTION

OVERSEAS SCHOOL OF COLOMBO SCHOOL COMMUNITY NETWORK (SCN) CONSTITUTION OVERSEAS SCHOOL OF COLOMBO SCHOOL COMMUNITY NETWORK (SCN) CONSTITUTION Introduction/Background: This updated constitution reflects the needs of the school community to define the role of the SCN as it

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 542, Approved and Ordered October 5, 2018 Executive Council Chambers, Victoria On the recommendation of the

More information

BVI Limited Partnership Hedge Funds: Calling Japan

BVI Limited Partnership Hedge Funds: Calling Japan BERMUDA BRITISH VIRGIN ISLANDS CAYMAN ISLANDS CYPRUS DUBAI HONG KONG LONDON MAURITIUS MOSCOW SÃO PAULO SINGAPORE conyersdill.com June 2012 BVI Limited Partnership Hedge Funds: Calling Japan Structuring

More information

DIAL/SELF Youth and Community Services YouthServe AmeriCorps Program

DIAL/SELF Youth and Community Services YouthServe AmeriCorps Program DIAL/SELF Youth and Community Services YouthServe AmeriCorps Program Site Partner Application Grant Cycle 2009-2012 Year 2009-2010 Application Deadline: March 4, 2009 Please email all materials to: Kate

More information

Integrity Applications, Inc. (Exact Name of Registrant as Specified in Its Charter)

Integrity Applications, Inc. (Exact Name of Registrant as Specified in Its Charter) Date of Report (Date of earliest event reported): October 29, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Registrant s telephone number, including area code: 972 (8) 675-7878

More information

INFINITY PHARMACEUTICALS, INC.

INFINITY PHARMACEUTICALS, INC. INFINITY PHARMACEUTICALS, INC. FORM 8-K (Current report filing) Filed 10/30/07 for the Period Ending 10/25/07 Address 780 MEMORIAL DRIVE CAMBRIDGE, MA 02139 Telephone 6174531000 CIK 0001113148 Symbol INFI

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We

More information

SUNDAY, MARCH 24 TUESDAY, MARCH 26, 2019 THE MAYFLOWER HOTEL, WASHINGTON, DC 20 Y E A R S CELEBRATING 20 YEARS OF QUALITY

SUNDAY, MARCH 24 TUESDAY, MARCH 26, 2019 THE MAYFLOWER HOTEL, WASHINGTON, DC 20 Y E A R S CELEBRATING 20 YEARS OF QUALITY SUNDAY, MARCH 24 TUESDAY, MARCH 26, 2019 THE MAYFLOWER HOTEL, WASHINGTON, DC 20 Y E A R S 1999-2019 CELEBRATING 20 YEARS OF QUALITY TOPICS AND THEMES FOR 2019 Behavioral Health and Improving Care for Serious

More information

Cancer Support Scotland AGM & Speakers Morning

Cancer Support Scotland AGM & Speakers Morning Cancer Support Scotland AGM & Speakers Morning Monday 19th September 2016 Cancer Support Scotland AGM & Speakers Morning 2016 This half day conference will focus on the needs of people affected by cancer

More information

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Regulatory Framework for Medical Devices in South Africa 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Medicines and Related Substances Act, 1965 (Act 101 of 1965) Act 72 of 2008 and

More information

Ministry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW

Ministry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions

More information

Sponsor. Exhibitor Information. Colorado NARO Board of Directors. Rob Prentice President. James Elder Vice President

Sponsor. Exhibitor Information. Colorado NARO Board of Directors. Rob Prentice President. James Elder Vice President Sponsor Exhibitor Information Colorado NARO Board of s Rob Prentice President James Elder Vice President Nancy Morford Treasurer & Secretary Robert Fowler Janice Bennett Good Terrel Shields Cynthia Simonds

More information

City of Carson 701 E. Carson St., Carson, CA Telephone: (310) ; ci.carson.ca.us

City of Carson 701 E. Carson St., Carson, CA Telephone: (310) ; ci.carson.ca.us OFFICE USE ONLY Case No. City of Carson 701 E. Carson St., Carson, CA 90745 Telephone: (310) 830-7600; ci.carson.ca.us Application Submittal Date Fee Accepted By SUPPLEMENTAL APPLICATION FOR COMMERCIAL

More information

For personal use only

For personal use only Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development

More information

The Health Innovation Partnership. Scott Johnstone Scottish Lifesciences Association

The Health Innovation Partnership. Scott Johnstone Scottish Lifesciences Association The Health Innovation Partnership Scott Johnstone Scottish Lifesciences Association Scottish Lifesciences Association CEO Scott Johnstone Scottish LifeSciences Landscape Health Innovation Partnership Overview

More information

Business Partner Program WELCOME. Thank you for your interest and support of the Denver legal community!

Business Partner Program WELCOME. Thank you for your interest and support of the Denver legal community! 2017-2018 Business Partner Program WELCOME Thank you for your interest and support of the Denver legal community! Mile High Chapter Business Partners receive benefits based on their level of sponsorship

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

Satellite Club or New Club The Right Fit

Satellite Club or New Club The Right Fit Satellite Club or New Club The Right Fit Table of Contents I. Introduction and History... 1 Governance of a Satellite Club... 2 II Satellite Club Strategy... 4 III Description and Process... 4 Purpose...

More information

Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation

Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

Annex 1. CHOONG YEE HOW List of past directorships. 1. Hong Leong Islamic Bank Berhad. 2. Promilia Berhad. 3. HL Asset Management Pte Ltd

Annex 1. CHOONG YEE HOW List of past directorships. 1. Hong Leong Islamic Bank Berhad. 2. Promilia Berhad. 3. HL Asset Management Pte Ltd Page 1 of 3 Change - Announcement of Appointment::Appointment of Director and Group President & Chief Executive Officer Issuer & Securities Issuer/ Manager Securities Stapled Security GUOCOLAND LIMITED

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

Corporate Presentation

Corporate Presentation www.xeneticbio.com NASDAQ: XBIO Enhancing Lives with Transformative Therapies Corporate Presentation May 2018 Forward Looking Statements This presentation contains forward-looking statements for purposes

More information

For personal use only

For personal use only ASX ANNOUNCEMENT 22 NOVEMBER 2017 AGM ADDRESSES FROM THE CHAIRMAN & CEO 22 November 2017 Cann Group Limited (ASX: CAN) is pleased to provide the following addresses to be delivered by its Chairman Allan

More information

The Dental Corporation Opportunity

The Dental Corporation Opportunity The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,

More information

Business Partner Program WELCOME. Thank you for your interest and support of the Denver legal community!

Business Partner Program WELCOME. Thank you for your interest and support of the Denver legal community! 2019-2020 Business Partner Program WELCOME Thank you for your interest and support of the Denver legal community! OVERVIEW OF Mile High Chapter Business Partners receive benefits based on their level of

More information